LMAT Quote, Financials, Valuation and Earnings

ResMed, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of 26.1%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat ResMed, Inc.'s return on equity of 25.6%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 23.74%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that LeMaitre Vascular, Inc. has higher upside potential than ResMed, Inc., analysts believe LeMaitre Vascular, Inc. is more attractive than ResMed, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.96%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. LeMaitre Vascular, Inc.'s net income of $17.4M is lower than ResMed, Inc.'s net income of $348.5M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.05x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.09x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -862.39%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat VolitionRX Ltd.'s return on equity of --.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 23.74%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than LeMaitre Vascular, Inc., analysts believe VolitionRX Ltd. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.96%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.05x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.09x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -1037.17%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Catheter Precision, Inc.'s return on equity of -192.05%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 23.74%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2161.97%. Given that Catheter Precision, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Catheter Precision, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.96%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.05x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.09x versus 7.90x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of 3.93%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 23.74%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.96%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.05x while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.09x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.